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Abstract
Background: Neuroinflammation plays a vital role in Alzheimer’s disease and other neurodegenerative conditions.
Microglia are the resident mononuclear immune cells of the central nervous system, and they play essential roles in
the maintenance of homeostasis and responses to neuroinflammation. The orphan G-protein-coupled receptor 55
(GPR55) has been reported to modulate inflammation and is expressed in immune cells such as monocytes and
microglia. However, its effects on neuroinflammation, mainly on the production of members of the arachidonic acid
pathway in activated microglia, have not been elucidated in detail.
Methods: In this present study, a series of coumarin derivatives, that exhibit GPR55 antagonism properties, were
designed. The effects of these compounds on members of the arachidonic acid cascade were studied in
lipopolysaccharide (LPS)-treated primary rat microglia using Western blot, qPCR, and ELISA.
Results: We demonstrate here that the various compounds with GPR55 antagonistic activities significantly
inhibited the release of PGE2 in primary microglia. The inhibition of LPS-induced PGE2 release by the most
potent candidate KIT 17 was partially dependent on reduced protein synthesis of mPGES-1 and COX-2. KIT 17
did not affect any key enzyme involved on the endocannabinoid system. We furthermore show that microglia
expressed GPR55 and that a synthetic antagonist of the GPR receptor (ML193) demonstrated the same effect
of the KIT 17 on the inhibition of PGE2.
Conclusions: Our results suggest that KIT 17 is acting as an inverse agonist on GPR55 independent of the
endocannabinoid system. Targeting GPR55 might be a new therapeutic option to treat neurodegenerative
diseases with a neuroinflammatory background such as Alzheimer’s disease, Parkinson, and multiple sclerosis (MS).
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Introduction
For many years, neuroinflammation has been known as a
common phenomenon in the pathology of many brain dis-
eases. Microglia, the principal cells involved in the innate
immune response in the central nervous system (CNS), play
essential roles in the maintenance of homeostasis and re-
sponses to inflammatory stimulus [1–3]. The over-activated
microglia has been associated with neurodegenerative dis-
eases such as Alzheimer’s disease (AD), Parkinson disease
(PD), and traumatic brain injury or aging [4, 5].
The GPR55 is an orphan G-protein-coupled receptor,
first described by Sawzdargo et al. in 1999 [6], and it is
not only highly expressed in CNS, but also in peripheral
tissue [7]. It can be activated by cannabinoids (CB) and
non-CB, leading to the hypothesis that it might be a pu-
tative “type-3” cannabinoid receptor [8]. However, in
contrast to the cannabinoid receptors CB1 and CB2,
GPR55 only couples to Gα12,13 proteins which leads to
the activation of the ras homolog gene family member A
(RhoA) and Rho-associated protein kinase (ROCK). The
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phospholipase C pathway is triggered by these proteins,
which increase the intercellular Ca2+ and extracellular
signal-regulated kinase (ERK) phosphorylation [9].
GPR55 is expressed in immune cells, such as monocytes,
natural killer (NK) cells [10], and microglia [11], and its in-
volvement in inflammation has been reported [10, 12, 13].
Activation of GPR55 by the agonist O-1602 increased
pro-inflammatory cytokines and cell cytotoxicity in mono-
cytes and NK cells stimulated with LPS [10]. Corroborat-
ing with this, an antagonist of GPR55, CID16020046, and
GPR55−/− knockout mice decreased the pro-inflammatory
cytokines in colitis mice models comparable to human in-
flammatory bowel disease (IBD) [12]. In hyperalgesia asso-
ciated with inflammatory and neuropathic pain, it was
observed to increase anti-inflammatory cytokines, IL-4
and IL-10, and also pro-inflammatory IFN-γ in GPR55−/−
knockout mice [13]. On the other hand, the GPR55 agon-
ist O-1602 decreased IL-6 and TNF-α in a model of ex-
perimental acute pancreatitis [14].
The roles of GPR55 in the pathophysiology of the CNS
are still not clear. In an excitotoxicity in vitro model of rat
organotypic hippocampal slice cultures (OHSC), the activa-
tion of GPR55 receptor by L-α-Lysophosphatidylinositol
(LPI) mediated neuroprotection through microglia [15]. In
a mouse model of PD, the expression of GPR55 was down-
regulated in the striatum and the treatment with an agonist
of GPR55, abnormal-cannabidiol, improved the motor be-
havior by neuroprotection of dopaminergic neuron cell
bodies [16]. A molecular, anatomical, electrophysiological,
and behavioral study of GPR55−/− knockout mice demon-
strated a normal development of brain structure and did
not affect the endocannabinoid system nor muscle strength
and motor learning. However, these mice presented deficits
in motor coordination and thermal sensitivity [17].
These studies suggest that GPR55 signaling can be
involved in neurodegeneration and modulate certain
cytokines and thus inflammation. However, its effects on
neuroinflammation, especially on the production of
members of the arachidonic acid pathway in activated
microglia, have not been elucidated in detail. We therefore
studied the effects of novel synthesized GPR55 antagonists
in LPS-activated microglia by examining prostaglandin E2
(PGE2) production, COX/mPGES-1 mRNA, and protein
levels. Furthermore, we evaluated the effect of KIT17 on
key enzymes involved in the endocannabinoid system such
as diacylglycerol lipase-α(DAGLα), monoacylglycerol lipase
(MAGL), α,β-hydrolase domain-containing 6 and 12
(ABHD6 and ABHD12), and fatty acid amide hydrolase
(FAAH).
Methods
Ethics statement
Animals were obtained from the Center for Experimental
Models and Transgenic Services-Freiburg (CEMT-FR). All
the experiments were approved and conducted according
to the guidelines of the ethics committee of the University
of Freiburg Medical School under protocol no. X-13/06A,
and the study was carefully planned to minimize the
number of animals used and their suffering. For the
activity-based protein profiling (ABPP), the experiments
were performed at Leiden University according to guide-
lines approved by the ethical committee of Leiden Univer-
sity (DEC#13191).
Chemicals
Synthetic GPR55 antagonists (Fig. 1) were synthesized at
the Institute for Organic Chemistry Karlsruhe - KIT
(Karlsruhe, Germany) [18] and dissolved in DMSO. The
number of the corresponding compounds in the Rempel
et al. 2013 paper are: KIT3 is 14, KIT17 is 37, and
KIT21 is 41. ML193 and O-1602 were obtained from
Tocris Biosciences. LPS from Salmonella typhimurium
(Sigma Aldrich, Deissenhofen, Germany) was resus-
pended in sterile phosphate-buffered saline (PBS, 5 mg/
mL) as stock and subsequently used at a final concentra-
tion (10 ng/mL) in the cultures.
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Fig. 1 Molecular structure of the synthesized compounds a KIT 3: 8-isopropyl-3-(2-methoxybenzyl)-5-methyl-2H-chromen-2-one, MW = 336,1725
g/mol. b KIT 17: 3-benzyl-6-hydroxy-7,8-dimethyl-2H-chromen-2-one, MW = 294,1256 g/mol. c KIT 21: 6-hydroxy-7,8-dimethyl-3-(2-methylbenzyl)-
2H-chromen-2-one, MW = 308,1412 g/mol
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Primary microglia cultures
As described in our previous studies [19–24], primary
mixed glial cell cultures were prepared from cerebral
cortices of 1-day neonatal Sprague-Dawley rats. Under
sterile conditions, the brains were carefully taken, and
the cerebral cortices were isolated and the meninges re-
moved. Then, the cortices were gently dissociated and
filtered through a 70-μm nylon cell strainer (BD biosci-
ences, Heidelberg, Germany). After centrifugation at
1000 rpm for 10 min, cells were collected and resus-
pended in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum (Biochrom AG, Berlin,
Germany) and antibiotics (40 U/mL penicillin and
40 μg/mL streptomycin, both from PAA Laboratories,
Linz, Austria). Cells were cultured on 10-cm cell culture
dishes (Falcon, Heidelberg, Germany) with density of
5 × 105 cells/mL in 10% CO2 at 37 °C (Heracell 240i,
Thermo Scientific). After 12 days in vitro, floating
microglia were harvested and re-seeded into 7 cm2 cul-
ture flask to give pure microglial cultures. On the next
day, medium was changed to remove non-adherent cells,
and after 1 h, the cells were stimulated for respective
experiments.
Determination of PGE2 release from LPS-activated
microglia
Cultured primary rat microglia were incubated with syn-
thesized compounds (KITs) (0.1–25 μM) or commercial
antagonist ML193 (10 μM) or agonist O-1602 (0.1–
10 μM) for 30 min. Afterwards, the cells were treated
with or without LPS (10 ng/mL) for the next 24 h. Su-
pernatants were harvested and levels of PGE2 were mea-
sured using a commercially available enzyme
immunoassay (EIA) kit (Assay Designs Inc., Ann Arbor,
MI, USA; distributed by Biotrend, Cologne, Germany).
The results were normalized to LPS and presented as
percentage of change in PGE2 levels of at least three in-
dependent experiments.
Cell viability assay
Viability of primary rat microglia after treatment with
the synthesized compounds was measured by the
CellTiter-Glo® Luminescent Cell Viability Assay (Pro-
mega), which is used to determine the number of meta-
bolically active and viable cells in cell culture based on
quantitation of the ATP present in the cells. Briefly, cells
were cultured in 96 well plates at the density of 25 × 103
cells/well for 24 h. Then, the medium was changed and
after at least 1 h, the cells were incubated with KIT 3,
KIT 17, and KIT 21 for 24 h. The compounds were dis-
solved in DMSO, and DMSO was used in the negative
control wells at final concentration of 0.15% and as a
positive control in a higher concentration (10%) during
experiments. The concentration of ATP was measured
after 24 h of incubation by adding 100 μL of reconsti-
tuted substrate and incubating for 10 min. Lumines-
cence was measured using a Modulus™ II Microplate
Multimode Reader (Turner BioSystems, USA).
RNA isolation and quantitative PCR
Quantitative real-time PCR (qPCR) was performed to
determine the presence of GPR55 in microglia and tran-
scriptional regulation of COX-1, COX-2, and mPGES-1
by synthesized compound (KIT17) in activated micro-
glia. Cultured primary rat microglia were left untreated
or incubated with LPS (10 ng/mL) in the presence or ab-
sence of KIT 17 (0.1–10 μM) which was added 30 min
before LPS (10 ng/mL) treatment for 4 h. Total RNA
was then extracted using the guanidine isothiocyanate
method [25]. The cDNA synthesis were reverse tran-
scribed from 1 μg of total RNA using Moloney Murine
Leukemia Virus (M-MLV) reverse transcriptase (Pro-
mega, Mannheim, Germany), RNase Inhibitor rRNasin®
(Promega), dNTP master mix (Invitek, Berlin, Germany),
and random hexamer primers (Promega). The real-time
PCR amplification was carried out by the CFX96 real-time
PCR detection system (Bio-Rad Laboratories, Inc.) using
iQ™ SYBR™ Green supermix (Bio-Rad Laboratories
GmbH, Munich, Germany). Reaction conditions were
3 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, 30 s
at 50 °C, and 45 s at 72 °C, and every cycle was followed
by plate reading. After that, 1 min at 95 °C, 1 min at 55 °
C, followed by melt curve conditions of 65 °C, 95 °C with
increment of 0.5 °C for 5 s, followed by final plate reading.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
served as an internal control for sample normalization,
and the comparative cycle threshold Ct method was used
for data quantification [26]. The primer sequences were as
follows:
GPR55: Fwd 5´-ACGTGGAGTGCGAGAGTCTT-3′;
Rev 5′-TGCCCATAGGAAGGAGGAA-5′;
COX-1: Fwd 5’-GCTCTTCAAGGATGGGAAACT-3′;
Rev 5’-TTCTACGGAAGGTGGGTACAA-3′;
COX-2: Fwd 5′-GGCTTACAAGACGCCACATCAC
CT-3′;
Rev 5′-TGGTTTAGGCGGCCGGGGAT-3′;
mPGES-1: Fwd 5′-TGCAGCACGCTGCTGGTCAT-3′;
Rev 5′-GTCGTTGCGGTGGGCTCTGAG-3′;
GAPDH: Fwd 5′-ATGCTGGTGCTGAGTATGTC-3′;
Rev 5′-AGTTGTCATATTTCTCGTGGGTT-3′.
Immunoblotting
Rat primary microglia were treated with KIT 17 (0.1–
10 μM) and control for 30 min; then, the LPS (10 ng/
mL) was added for 24 h. After the experiment, the cells
were washed with cold PBS and lysed in the lysis buffer
(42 mM Tris–HCl, 1.3% sodium dodecyl sulfate, 6.5%
glycerin, 100-μM sodium orthovanadate, and 2%
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phosphatase and protease inhibitors). Protein concentra-
tion of the samples was measured using the bicinchoni-
nic acid (BCA) protein assay kit (Thermo Fisher
Scientific, Bonn, Germany) according to the manufac-
turer’s instructions. For Western blotting, 10–20 μg of
total protein from each sample was subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing conditions. Afterward, pro-
teins were transferred onto polyvinylidene fluoride
(PVDF) membranes (Merck Millipore, Darmstadt,
Germany) by semi-dry blotting. After blocking with
Roti-Block (Roth, Karlsruhe, Germany), membranes
were incubated overnight with primary antibodies. Pri-
mary antibodies were goat anti-COX-2 (1:500; Santa
Cruz Biotechnology, Heidelberg, Germany), rabbit
anti-mPGES-1 (1:6000; Agrisera, Vännas, Sweden), and
rabbit anti-actin (1:5000; Sigma Aldrich). The proteins
were detected with horseradish peroxidase-coupled
rabbit anti-goat IgG (Santa Cruz, 1:100,000 dilution) or
goat anti-rabbit IgG (Amersham, 1:25,000 dilution) using
enhanced chemiluminescence (ECL) reagents (GE
Healthcare, Freiburg, Germany). Densitometric analysis
was performed using ImageJ software (NIH, USA), and
β-actin control was used to confirm equal sample load-
ing and normalization of the data.
Cyclooxygenase activity assay in primary microglia
culture
Under unstimulated conditions, primary microglial cells
only express the COX-1 isoform [27]. To measure
COX-1 activity, primary rat microglial cells were plated
in 24-well cell culture plates. After 24 h, medium was re-
moved and replaced with serum-free medium. KIT 17
(0.1–10 μM) or the selective reversible COX-1 inhibitor
SC560 (1 and 10 μM) was added and left for 15 min.
Then, 15 μM of arachidonic acid were supplemented for
another 15 min. Supernatants were then collected and
used for the determination of PGE2.
To measure COX-2 activity, primary rat microglial
cells were plated in 24-well cell culture plates and
pre-incubated with LPS (10 ng/mL) for 24 h. Then,
medium was removed and replaced with serum-free
medium. KIT 17 (0.1–10 μM) or diclofenac sodium
(preferential COX-2 inhibitor, 10 μM) was added and left
for 15 min. Then, 15 μM of arachidonic acid was supple-
mented for another 15 min. Supernatants were then col-
lected and used for determination of PGE2.
Activity-based protein profiling (ABPP) in mouse brain
proteome
The mouse brain proteome preparation and gel-based
ABPP was performed as previously described [28, 29].
Mouse tissues were homogenized in lysis buffer A (20 mM
HEPES pH 7.2, 2 mM DTT, 1 mM MgCl2, 25 U/mL
Benzonase) and incubated for 5 min on ice. To remove
containing debris, the suspension was low speed centri-
fuged (× 2500g, 3 min, 4 °C). The resulting supernatant was
subjected to ultracentrifugation (× 100.000g, 45 min. 4 °C,
Beckman Coulter, Type Ti70 rotor) to separate the mem-
brane fraction as a pellet and the cytosolic fraction in the
supernatant. The pellet was resuspended in storage buffer
(20 mM HEPES pH 7.2, 2 mM DTT). The total protein
concentration was determined with Quick Start Bradford
assay (Bio-Rad). Membranes and supernatant were stored
in small aliquots at − 80 °C until use. For the gel-based
ABPP, mouse brain membrane proteome (2 mg/mL) were
pre-incubated with 0.5 μL vehicle (DMSO) or 0.5 μL KIT
17 (in DMSO) for 30 min at room temperature. Followed
by treatment with the activity-based probes tetramethylro-
damine 5-carboxamdio fluorophosphonate (TAMRA-FP,
100 nM final concentration) and MB064 (250 nM final
concentration) for 15 min at room temperature. The reac-
tions were quenched by addition of 10 μL 3 × SDS-PAGE
sample buffer, and the samples were directly loaded and re-
solved on SDS-PAGE gel (10% acrylamide). The gels were
scanned with a Bio-Rad Chemidoc (Bio-Rad Laboratories
B.V.) using settings for Cy3 and TAMRA (excitation wave-
length 532 nm, emission wavelength 580 nm) and analyzed
with ImageLab (5.2.1, Bio-Rad Laboratories B.V.).
Statistical analysis
Statistical analyses were performed using Prism 5 software
(GraphPad software Inc., San Diego, CA, USA). Values of
all experiments were represented as mean ± SEM of at
least three independent experiments. Raw values were
converted to percentage and compared using one-way
ANOVA with post hoc Student-Newman-Keuls test (mul-
tiple comparisons). The level of significance was consider
as *p < 0.05, **p < 0.01, and ***p < 0.001.
Results
Expression of GPR55 in primary rat microglia
To prove that microglial cells express GPR55, we studied
the mRNA levels of GPR55 in primary rat microglia with
or without LPS stimulation. We observed the GPR55
mRNA is expressed in microglial cells and the stimula-
tion with 10 ng/mL LPS did not affect the expression of
this receptor (Additional file 1).
Effects of antagonists of the GPR55 receptor on PGE2
release in LPS-stimulated primary microglial cells
We further investigated the effects of 21 chemical-re-
lated GPR55 receptor antagonists (KIT 1-KIT 21) on
LPS-induced PGE2 synthesis in microglia cells. We se-
lected some of the active KIT compounds, KIT 3, KIT
17, and KIT 21 (Fig. 1), from the first screening (Add-
itional file 2) due to activity of 90–100% PGE2 inhibition
and the availability of the compound for further studies.
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When treated with LPS, primary microglial cells pro-
duced robust amounts of PGE2 (2596.13 pg/mL, consid-
ered as 100%) compared to the untreated control
(326.59 pg/mL) and this increase was inhibited by the
three synthesized compounds (KIT 3, KIT 17, and KIT
21) in a concentration-dependent manner (Fig. 2).
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Fig. 2 Effects of different KIT compounds on the release of PGE2 in
LPS-activated microglia. Microglia were pre-treated with KIT 3 (a), KIT
17 (b), or KIT 21 (c) (0.1–25 μM) for 30 min; afterwards, cells were
incubated with or without LPS (10 ng/mL) for the next 24 h. Cell
supernatants were then collected, and release of PGE2 was measured
by enzyme immune assay (EIA). Values are presented as the mean ±
SEM of at least 3 independent experiments. Statistical analyses were
carried out by using one-way ANOVA and Newman-Keuls post hoc
test with *p < 0.01, **p < 0.05, and ***p < 0.001 compared to LPS group
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Fig. 3 Evaluation of cell viability of microglial cells treated with
different KIT compounds. Microglia cells were exposed with different
concentrations of KIT 3 (a), KIT 17 (b), or KIT 21 (c) for the next 24 h.
Cell viability was measured based on quantitation of ATP present in
the cells, and data were normalized as percentage of negative
control. Values are presented as the mean ± SEM of at least three
independent experiments. Statistical analyses were carried out by
using one-way ANOVA and Newman-Keuls post hoc test with
*p < 0.05, **p < 0.01, and ***p < 0.001 compared to negative group
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All three compounds tested, statistically, prevented the
increase on levels of PGE2 at the concentrations of 10
and 25 μM. Furthermore, the KIT 17 (Fig. 2b) also sta-
tistically prevented at the concentration of 1 and 5 μM.
Effects of GPR55 receptor antagonists on cell viability
We performed a cell viability assay to exclude the possibil-
ity that the inhibitory effects of the synthesized com-
pounds observed were due to a reduction of cell viability.
The effects of KIT 3, KIT 17, and KIT 21 on cell viability
were studied using an ATP assay in primary microglial
cells. The incubation with LPS or the compounds did not
change cell viability compared to vehicle (DMSO) (Fig. 3).
A significant increase in ATP was observed with the con-
centration of 10 μM KIT 3 (Fig. 3a) and 1 μM KIT 17
(Fig. 3b). DMSO in the high concentration of 10% was
used as positive control, and it strongly affected cell viabil-
ity of microglial cells (Fig. 3, right column).
Since KIT 17 showed a desirable inhibitory profile on
PGE2 release and had no negative impact on cell viabil-
ity, even increased ATP levels, we used KIT 17 for the
mechanistic follow-up experiments.
KIT 17 as well as the known GPR55 antagonist ML
potently inhibited LPS-induced PGE2 release whereas the
GPR55 agonist O-1602 did not affect the PGE2 levels in
microglial cells
We further investigate the effects of a commercial antag-
onist (ML193) and an agonist of GPR55 (O-1602) on
PGE2 release in LPS-stimulated primary microglial cells.
ML193 (10 μM) potently and statistically prevented
LPS-induced increase of PGE2 levels by 90%, and a com-
parable inhibition was observed using KIT 17 (85% in-
hibition) (Fig. 4a). A potent agonist of GPR55, O-1602
(0.1–10 μM), did not affect the LPS-induced PGE2 re-
lease as well as did not interfere with the effects of
ML193 and KIT 17. O-1602 also did not alter basal
PGE2 levels (Fig. 4b).
Activity-based protein profiling on mouse brain proteome
for selectivity and off-target activity of KIT 17
Our previous study demonstrated the effects of KITs
compounds on GPR55, CB1, CB2, and GPR18 receptors
[18], in which KIT 17 showed inhibitory effects on
GPR55 and CB2 receptors. To investigate its
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Fig. 4 Effects of the commercial GPR55 antagonist ML193 (a) and agonist O-1602 alone and in combination with ML 193 and KIT17 (b) on PGE2
release in LPS-stimulated primary microglial cells compared to KIT 17 alone
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involvement on other members the endocannabinoid
system, we further evaluated the selectivity of KIT 17 on
key enzymes involved in the endocannabinoid system
[diacylglycerol lipase-αDAGLα, monoacylglycerol lipase
(MAGL), α,β-hydrolase domain-containing 6 and 12
(ABHD6 and ABHD12), and fatty acid amide hydrolase
(FAAH)]. To this end, we used the approach of
gel-based activity-based protein profiling (ABPP) on a
mouse membrane brain proteome. As shown in Fig. 5,
we did not find any off-target interactions of KIT 17 in
the concentrations of 0.1–10 μM. This indicates that
KIT 17 showed a highly selective profile against GPR55
and CB2, as no significant reduction of any other endo-
cannabinoid enzyme in the mouse brain proteome was
observed in this experimental setting.
Effects of KIT 17 on COX-2 and mPGES-1 mRNA and protein
synthesis in LPS-stimulated primary microglial cells
Prostaglandins are synthesized through enzymes COX-2
and mPGES-1 under an inflammatory stimulus [30]. As
shown in Fig. 6, LPS induced the expression and the pro-
tein synthesis of COX-2 and mPGES-1. We observed that
LPS-induced mPGES-1 synthesis was significantly
inhibited by KIT 17 in a concentration-dependent manner
starting at the concentration of 5 μM and revealing max-
imal effects using 10 μM, which decreased mPGES-1
levels about approx. 70%, if compared to LPS control
(Fig. 6c). However, no effects were observed on mRNA ex-
pression of mPGES-1 at the 4-h time point (Fig. 6a).
Furthermore, we investigated whether KIT 17 affected
COX-2 mRNA expression and protein synthesis. The
pre-treatment with KIT 17 in microglial cells showed a
significant concentration-dependent decrease of LPS-in-
duced COX-2 mRNA expression (Fig. 6b) and protein
synthesis (Fig. 6d) starting at 1 μM and maximal effects
using 10 μM, which decreased approximately 60% and
30% of COX-2 mRNA and 70% and 40% of protein levels,
respectively, if compared to the LPS control.
We also evaluated the effect of KIT 17 on COX-1
mRNA expression (Additional file 3) showing a down-
regulation of COX-1 mRNA expression by LPS stimula-
tion and no modulatory effect of KIT17.
Effects of KIT 17 on enzyme activity of COX-1 and COX-2
Thus, we extended our study to investigate if these ro-
bust inhibitory effects of KIT 17 on PGE2 release were
Fig. 5 Effects of KIT 17 on key enzymes involved in the endocannabinoid system. Dose-response gel-based ABPP on mouse membrane brain
proteome with activity-based probes TAMRA-FP (left) and MB064 (right) (N = 3). ABHD6 and ABHD12 α,β-hydrolase domain-containing 6 and 12;
DAGLα diacylglycerol lipase-α; FAAH fatty acid amide hydrolase, and MAGL monoacylglycerol lipase
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additionally due to a direct suppression of COX enzym-
atic activity. As shown in Fig. 7a, COX-1 activity was
even increased by KIT 17 in the concentrations of 0.1–
10 μM, whereas in COX-2 activity was not affected
(Fig. 7b). The control inhibitors for COX-1 (SC560) and
COX-2 (diclofenac) showed the expected inhibitory ef-
fects (last 2 columns on the right).
Discussion
Neuroinflammatory processes are considered a double-
edged sword, having both protective and detrimental ef-
fects in the brain [31–33]. Microglia, the resident innate
immune cells of the brain, are a key component of neu-
roinflammatory response. There is a growing interest in
developing drugs to target microglia and control neu-
roinflammatory processes [34, 35]. We have developed a
new series of GPR55 receptor antagonist compounds de-
rived from the coumarin structure which, in general, ex-
hibit a promising profile as GPR55 receptor ligands with
antagonistic activity [18].
In the current study, we demonstrated the anti-neu-
roinflammatory effect of these synthesized compounds
in LPS-activated primary microglial cells by inhibiting
PGE2 release and downregulating mPGES-1 and COX-2
protein levels. We furthermore show that microglia
expressed GPR55 and that a synthetic antagonist of the
GPR55 receptor (ML193) revealed comparable effects as
KIT 17 on the inhibition of LPS-induced PGE2. Further-
more, we demonstrated that KIT 17 did not affect any
enzyme involved in the endocannabinoid system in the
mouse brain proteome.
Monocytes and macrophages express an extensive rep-
ertoire of G-protein-coupled receptors (GPCRs) that
regulate inflammation and immunity [11, 36]. Among
these receptors, the role of GPR55 in the perspective of
neurological diseases and in microglia activation is
controversial. GPR55 is expressed in many mammalian
tissues including several brain regions [6, 37]. Pietr et al.
(2009) showed that GPR55 mRNA is significantly
expressed in both, primary mouse microglia and the
BV-2 mouse microglial cell line, and the stimulation
with LPS downregulated GPR55 expression [11]. How-
ever, in a study using primary rat microglial cells culture,
the GPR55 transcript was detected in non-stimulated
and LPS-stimulated cells, demonstrating no alterations
of its levels [38]. Collaborating with this finding, we were
able to confirm the expression of GPR55 in primary rat
microglia and that the stimulation with LPS did not
affect the expression of the receptor. Further studies,
probably using microglia cell lines, have to be performed
to demonstrate the functional GPR55 receptors on
microglial cells.
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Fig. 6 Effects of KIT 17 on mRNA expression and protein synthesis of mPGES-1 (a, c) and COX-2 (b, d) in LPS-stimulated primary microglial cells.
a, b Cells were pre-treated with different concentrations of KIT 17 for 30 min before stimulating with LPS. After 4 h, mPGES-1 (a) and COX-2 (b)
were measured by qPCR. Western blot analysis of protein levels of mPGES-1 (c) or COX-2 (d) in cells pre-treated with different concentrations of
KIT 17 for 30 min following LPS stimulation for 24 h. Protein levels were normalized to β-actin loading control (n = 3–4). *p < 0.05, **p < 0.01, and
***p < 0.001 with respect to LPS (one-way ANOVA followed by the Newman-Keuls post hoc test)
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We next studied the potential role of GPR55 in
microglia-mediated neuroinflammation by studying the
effects of the KIT compounds on prostaglandin synthe-
sis. Microglial cells are the resident macrophages of the
CNS and the most important source of PGE2 in neuro-
inflammation. As shown before, the stimulation of pri-
mary microglia with LPS strongly increases PGE2 and
COX-2 expression [39–41].
The main finding of our study is that the various syn-
thesized KIT compounds decreased PGE2 release in
LPS-treated microglia and upstream members of the
arachidonic acid pathway (COX-2/mPGES-1) without
affecting the viability of microglia. Moreover, the similar
inhibition of PGE2 was observed using the commercially
available GPR55 antagonist ML193. Interestingly, the
agonist O-1602 did not affect the inhibitory effect of
ML193 as well as KIT 17 and also showed no effect on
basal PGE2 levels when applied without LPS.
KIT 17 and the other KIT compounds tested were syn-
thesized by Rempel and collaborators (2013) as a series of
coumarin derivatives (KITs) targeting GPR55 (formerly
also known as CB3 receptor).
However, the compounds, including KIT 17, also bind
to other receptors such as CB1, CB2, and GPR18 recep-
tors, suggesting that the observed activities of KIT 17
are possible mediated also by other receptors [18]. The
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Fig. 7 Effects of KIT 17 on COX-1 (A) and COX-2 (b) enzyme activity in primary microglia cells. a For COX-1 activity assay, cells were treated with
different concentrations of KIT 17 for 15 min before addition of 15 μM of arachidonic acid. PGE2 in the supernatants was measured after additional
15 min. b Cells were stimulated for 24 h with LPS (10 ng/mL) and then treated with different concentrations of KIT 17 for 15 min. Then, 15 μM of
arachidonic acid was added and PGE2 in the supernatants was measured by enzyme immune assay (EIA). Data are expressed as mean ± S.E.M. of at
least 3 independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to control (one-way ANOVA followed by the Newman-Keuls post
hoc test)
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inhibitory values for KIT 17 on GPR55 is 9.32 ± 1.05
[IC50 (μM± SEM)] but it also binds to CB2 [Ki ± SEM
(μM) 3.42 ± 0.90], whereas only weak binding was ob-
served for CB1 and GPR18 [Ki ± SEM (μM)/IC50 ≥ 10]
[18]. These data suggest that we can exclude CB1 and
GPR18 as potential other receptors involved in the
anti-inflammatory effects observed in microglial cells,
but we cannot exclude an additional or exclusive in-
volvement of CB2. The fact that KIT 17 as a GPR55 or
CB2 antagonist is inhibiting TLR4-mediated inflamma-
tion, suggests an inverse agonistic activity of KIT 17 on
GPR55 or CB2. To confirm this hypothesis and to prove
a possible involvement of CB2, we used AM630, a com-
pound with CB2 inverse agonistic activity with a Ki of
32 nM [42], also showing antagonistic activities on CB2.
As shown in Additional file 4, AM630 also inhibited
LPS-induced PGE2 release in a comparable inhibitory
profile on LPS-induced PGE2 as KIT 17 with a slight
more activity using 1 μM. However, the Ki of AM630
(32 nM) is 100 fold lower towards CB2 then the one of
KIT 17 (3.42 μM on CB2), implicating a more potent ef-
fect of AM630 on PGE2 release induced by LPS then
KIT 17, if we assume a CB2-mediated effect. Since the
inhibitory activity of AM630 on LPS-induced PGE2 re-
lease is only marginally higher than the effect of KIT 17,
we conclude that CB2 is most likely not mediating the
effects of KIT 17 and that AM630 might even also act
via GPR55 on the observed effects. More studies have to
be performed to support this conclusion, since there are
to our knowledge no data available on the effects of
AM630 on GPR55.
Since the GPR55 is described to be linked to the endo-
cannabinoid system and due to the fact that the KIT
compounds are also binding to CB1 and CB2, we were
further interested in other interactions between KIT 17
and other members of the endocannabinoid system.
Using the activity-based protein profiling on mouse
brain proteome for selectivity and off-target activity ap-
proach, we did not find any interactions between KIT 17
and the endocannabinoid enzymes DAGLα, MAGL,
Fig. 8 Graphical abstract showing the anti-neuroinflammatory effects of the KIT 17 in LPS-activated microglia. The anti-inflammatory effects of KIT
17 included the reduction of COX-2/mGES-1 levels as well as potent inhibition of PGE2 production
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ABHD6, ABHD12, and FAAH. An interaction or effects
of GPR55 activation on these enzymes have not been de-
scribed to our knowledge in the literature yet.
Thus, our data strongly suggest that PGE2 inhibitory
effects in are most likely mediated by GPR55, although
other mechanism independent of GPR55 and CBs in the
observed effects cannot be excluded. The involvement of
GPR55 in the activation of the arachidonic acid cascade
during microglia activation and neuroinflammation has
not been reported yet. The potential role in peripheral
inflammation has been studied with GPR55 antagonists
or knockout mice. The GPR55 inhibitor CID16020046
reduced TNF-α, IL-1β, IL-6, and COX-2 levels in a
mouse model of intestinal inflammation [12]. In a mouse
model of colorectal cancer, the levels of COX-2 and
PGF2α were decreased in GPR55
−/− [43]. In hyperalgesia
associated with inflammatory and neuropathic pain, an
increase of anti-inflammatory cytokines, IL-4, and IL-10
has been observed in GPR55−/− knockout mice [13].
These data also suggest that GPR55 might be the medi-
ator of the anti-neuroinflammatory effects of KIT17 as
observed in this study.
In accordance with the diverse and complex pharma-
cology of GPR55, no data yet existed regarding the effi-
cacy of GPR55 antagonists on COX-1/2 activity. Thus,
we elucidated whether the robust inhibitory effects of
KIT 17 on LPS-induced PGE2 release is due to a direct
inhibition of COX enzymatic activity, the mechanism of
action of most NSAIDs. We demonstrate here, that
COX-1 activity was increased by KIT 17 in the doses of
1–25 μM, whereas in COX-2 activity was not affected.
The control inhibitors for COX-1 (SC560) and COX-2
(diclofenac) showed the expected inhibitory effects. This
suggests that the PGE2 inhibiting effects of KIT 17 and
most likely by the other KIT compounds is not due a
direct inhibition of COX activity. The COX-1 inducing
effects might even have positive benefits, since COX-1 is
protecting the gut mucosa and its inhibition by some
NSAIDs cause gastro-intestinal side effects [44, 45].
Conclusions
As illustrated in the graphical abstract (Fig. 8), we provide
the evidence that KIT 17 and the other KIT coumarin
derivates and GPR55 antagonists effectively block micro-
glia activation in terms of attenuation of both PGE2
production and mPGES-1/COX-2 levels. Our data
provide evidence that the anti-neuroinflammatory ef-
fects are mainly mediated by GPR55, most likely via
an inverse agonistic activity. However, further experi-
ments are necessary to better comprehend the mech-
anistic effects of KIT compounds and the involvement
of GPR55 receptors. Our study suggests that GPR55
antagonists might be a new therapeutic option for the
treatment of neuroinflammation-, neurodegeneration-,
and neuroinflammation-related diseases.
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